Ignota Labs

Ignota Labs reviews advances in toxicity prediction, including modeling methods and new data like organ-on-a-chip studies.

Dr Layla Hosseini-Gerami tells Nature how AI is transforming science and how to keep it accountable: AI gathers evidence, scientists validate it.

At a Gordon Research Conferences seminar, Dr Layla Hosseini-Gerami sets out best practice for AI in small-molecule toxicology: data, models and evaluation.

On the Beyond the Clinic podcast, CEO Sam Windsor explains how Ignota Labs uses AI to find out why drugs failed and give them a second chance.

Aylesbury High School unveils a purple plaque for former pupil Dr Layla Hosseini-Gerami, Ignota Labs co-founder and Innovate UK Women in Innovation winner.

BBC Persian Click interviews Ignota Labs co-founder Dr Layla Hosseini-Gerami about her career and rescuing failed drugs with AI. The interview is in Farsi.

Dr Jordan Lane joins a Bio Integrates 2025 panel on building an AI strategy for biotech that delivers real value while managing the risks.

Ignota Labs is one of 10 winners of the AI for Science Datasets RFP, building a dataset with Arctoris on the root causes of drug toxicity and how to fix them.

Ignota Labs applies AI to repurpose drugs, including a SYK inhibitor for ITP and wAIHA, a PDE9 inhibitor for kidney and cardio-metabolic disease, and a CDK9 inhibitor for AML.

Ignota Labs CSO Dr Jordan Lane on the Careers in Discovery podcast: building conviction, the opportunity in failed research, and why risk is relative.

Ignota Labs introduces its team, including co-founders, leadership, board members, scientific advisors, partners, and investors.

Ignota Labs uses AI to identify safety failures in promising drugs and redesigns them for clinical use.

Ignota Labs explains its data collection, usage, and protection policies under UK GDPR, including user rights to access, correct, or object to data use.